Regulatory Transactions

From: Camarillo Acorn

From: The White House

***

Secretary Mnuchin is a leader in our effort to make America competitive again.  We’re going to make it great again, we’re going to make it strong again, we’re going to make it safe again, and we’re going to make it competitive again.  I’m also issuing two directives that instruct Secretary Mnuchin to review the damaging Dodd-Frank regulations that failed to hold Wall Street firms accountable.  I mean, they’ve done really, in many cases, the opposite of what they were supposed to.  These regulations enshrine “too big to fail” and encourage risky behavior.

From: Aggregates Manager

Kerry Clines

When the Trump administration asked for recommendations on ways the government could cut regulations and make it easier for companies to get their projects approved, the National Stone, Sand & Gravel Association (NSSGA) responded, along with 167 others. According to the Washington Post, three senior administration officials from different departments say that the White House is inclined to accept many of the suggestions.

Some of the most notable comments include the following:

Read Complete Article

From: Financial Times

US Treasury secretary speaks to the FT on tax, economic growth, and North Korea

by: Sam Fleming, Demetri Sevastopulo and Shawn Donnan

***

. . . .So one of the things I’m very focused on in my role at FSOC is re-looking at, with the regulatory agencies, the definitions of the Volcker rule, and making sure that it provides proper liquidity. That’s one of the things that has come up already in our review of the financial reforms under the executive order, and we’ve begun to have discussions.

From: P&T Community

Stephen Barlas

The Food and Drug Administration (FDA) has put one more piece of the biosimilar puzzle in place by issuing final guidance on naming of biological innovator products and bio-similars.1 The agency hewed close to the thinking it first noted in an August 2015 proposed rule and guidance that would “name” a biosimilar by using its non-proprietary name separated from a random four-letter suffix by a hyphen.2,3 That format satisfied almost no one, and brand-name and generics manufacturers, as well as pharmacy groups, got almost none of the changes they requested.